Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject has a confirmed diagnosis of myelofibrosis, including PMF, post-PV MF, and post-ET MF.~2. Subject has been receiving ruxolitinib therapy for intermediate or high-risk myelofibrosis for \>6 months prior to enrollment with no more than 1 dose reduction of ruxolitinib in the 2-8 weeks prior to enrollment and a stable daily dose ≥5 mg twice daily (BID) \>2 months prior to enrollment.~3. Subject has MF with evidence of persistent disease despite ruxolitinib monotherapy treatment, consisting of:~   1. Persistent or worsening disease-related symptoms, including but not limited to fatigue, pruritus, night sweats, early satiety, and other symptoms as determined by a MPN-SAF TSS score of \>20 points; AND~  2. Documented splenomegaly of at least 5 cm below the costal margin as measured on inspiration by physical exam.~4. Subject has an Eastern Cooperative Oncology Group performance status of 0-2.~5. Acceptable pre-study organ function during screening defined as:~   1. Absolute neutrophil count (ANC) ≥ 1000/uL~  2. Hemoglobin (hgb) ≥ 8.0 g/dL (may be supported with transfusion)~  3. Platelets (plt) ≥ 75,000/uL~  4. AST/SGOT and ALT/SGPT ≤2 x Upper Limit of Normal (ULN)~  5. Direct serum bilirubin ≤ 1.5 x ULN~  6. Creatinine clearance \>50 mL/min/1.73 m2 based on Cockcroft Gault equation.~Exclusion Criteria:~1. Subject has known active liver disease, including viral hepatitis or cirrhosis.~2. Subject has known or suspected HIV or other active infections requiring acute or chronic treatment with systemic antibiotics. Conditions requiring topical antibiotics are acceptable.~3. Subject has a QTcF \> 480 ms (corrected) in the screening or baseline ECG.~4. Subject has left ventricular ejection fraction (LVEF) ≤ 50%, or below institution's lower limit of normal (whichever is lower) by echocardiogram (ECHO) or multigated acquisition (MUGA) scan.~5. Subject has a history (or family history) of long QT syndrome.~6. Subject has coronary artery disease with an ischemic event within 6 months prior to enrollment.~7. Subject has a permanent cardiac pacemaker.~8. Subject has history of a second primary malignancy within the past 2 year except for the following (if appropriately treated and considered cured): stage I endometrial, surgically treated cervical or prostate carcinoma, and non-melanoma skin cancer.~9. Subject has significant uncontrolled medical condition within 6 months prior to enrollment, as determined by the investigator.~10. Subject has concurrent participation in any interventional studies within 14 days of first dose of study drug.~11. Subject has uncontrolled diabetes mellitus, in the judgment of the Principal Investigator.~12. Subject has an active ocular condition that in the opinion of the investigator may alter visual acuity during the course of the study (i.e., ocular inflammatory disease etc.) or a history or anticipation of major ocular surgery (including cataract extraction, intraocular surgery, etc.) during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose 1: PU-H71 225 mg/m2 + ruxolitinib (Type: EXPERIMENTAL): Cohort 1
- Dose 2: PU-H71 300 mg/m2 + ruxolitinib (Type: EXPERIMENTAL): Cohort 2
- Dose 3: PU-H71 400 mg/m2 + ruxolitinib (Type: EXPERIMENTAL): Cohort 3
- Dose 4: PU-H71 600 mg/m2 + ruxolitinib (Type: EXPERIMENTAL): Cohort 4

Based on this trial design, predict the completion outcome and termination type (if applicable).